8-K: Allarity Therapeutics Reports Extended Treatment Success with Stenoparib in Ovarian Cancer Trial

Allarity Therapeutics announced that two patients in its Phase 2 ovarian cancer trial have exceeded one year on stenoparib therapy, demonstrating durable clinical benefit.

Summary

• Allarity Therapeutics has reported that two patients in their Phase 2 clinical trial for stenoparib, a dual PARP/Tankyrase inhibitor, have been on treatment for over a year.
• These patients were pre-selected using Allarity's Drug Response Predictor (DRP) companion diagnostic, which indicated a high likelihood of benefit from stenoparib.
• The trial is evaluating stenoparib's safety and efficacy, and has shown a confirmed complete response and long-term disease stability in multiple patients.
• The patients in the trial had advanced, recurrent ovarian cancer and had previously undergone multiple lines of therapy.
• The DRP companion diagnostic uses a transcriptomic signature of 414 mRNA biomarkers to predict drug response.
• Patients with DRP scores above 50 were selected for the trial.
• The stenoparib dosing regimen was revised in Q1 2023 to twice-daily dosing (200 mg morning, 400 mg evening) from a previous once-daily 600 mg dose.
• Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential to inhibit the Wnt signaling pathway.

Sentiment

Score: 8

Explanation: The document presents positive clinical results with patients exceeding one year on therapy, indicating a strong potential for the drug. The use of a companion diagnostic and the novel mechanism of action further contribute to a positive outlook. However, the risks associated with clinical trials and regulatory approval temper the sentiment slightly.

Positives

• The extended treatment duration of over one year on stenoparib is a significant achievement for heavily pre-treated ovarian cancer patients.
• The DRP companion diagnostic appears to be effective in identifying patients likely to benefit from stenoparib.
• Stenoparib's unique dual mechanism of action as a PARP and Tankyrase inhibitor offers a novel approach to cancer treatment.
• The trial has shown a confirmed complete response and long-term disease stability for multiple patients.
• The revised twice-daily dosing regimen of stenoparib appears to be effective.

Risks

• The company's ability to raise sufficient capital to support clinical trials is a risk.
• Early clinical results may not predict final outcomes, and results may change with more data.
• Clinical study results are subject to interpretation and may require additional analysis.
• Regulatory approval for stenoparib is not guaranteed.
• There is a risk of cessation or delay of ongoing or planned clinical trials.
• Results from previous studies may not be repeated in future studies.

Future Outlook

Allarity is actively planning the further advancement of its stenoparib program, with a focus on accelerating its path toward regulatory approval. The Company remains dedicated to exploring stenoparibs long-term clinical benefit in DRP-selected patients and is preparing for the next phase of development. Additional updates on the programs progress and future trials will be shared in the coming months.

Management Comments

• Thomas Jensen, CEO of Allarity Therapeutics, stated that they are incredibly encouraged by the sustained clinical benefit seen in these patients.
• Thomas Jensen noted that extending life by 52 weeks is particularly noteworthy for heavily pre-treated ovarian cancer patients.
• Dr. Fernanda B. Musa, Director of Clinical Research in Gynecology Oncology, expressed surprise and excitement at the long duration of response to stenoparib.
• Dr. Musa credited the success to personalized medicine, pairing the therapy to the patients specific tumor profile.

Industry Context

This announcement highlights the growing trend of personalized medicine in cancer treatment, using companion diagnostics to identify patients most likely to benefit from specific therapies. The development of dual-targeted inhibitors like stenoparib also reflects the industry's focus on novel mechanisms of action to overcome treatment resistance.

Comparison to Industry Standards

• The reported one-year treatment duration is notable, as many ovarian cancer patients progress through available therapies in a few months.
• The use of a companion diagnostic to select patients is consistent with the trend towards personalized medicine, similar to how companies like Foundation Medicine and Guardant Health use genomic profiling to guide treatment decisions.
• The dual PARP/Tankyrase inhibition mechanism of stenoparib is a novel approach, differentiating it from standard PARP inhibitors like olaparib (Lynparza) and niraparib (Zejula).
• The trial's focus on heavily pre-treated patients is similar to other trials evaluating novel therapies in advanced cancer settings, such as those conducted by companies like Clovis Oncology and Tesaro (now part of GSK).

Stakeholder Impact

• Shareholders may view the positive clinical results as a positive sign for the company's future.
• Patients with advanced ovarian cancer may see stenoparib as a promising new treatment option.
• Employees may be encouraged by the progress of the clinical trial.
• The company's success could lead to increased interest from potential partners and investors.

Next Steps

• Allarity is actively planning the further advancement of its stenoparib program.
• The company is focusing on accelerating the path toward regulatory approval.
• Allarity will continue to explore stenoparibs long-term clinical benefit in DRP-selected patients.
• The company is preparing for the next phase of development.
• Additional updates on the programs progress and future trials will be shared in the coming months.

Key Dates

Keywords

stenoparib, ovarian cancer, PARP inhibitor, Tankyrase inhibitor, DRP, companion diagnostic, clinical trial, personalized medicine, drug response predictor